Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 4Other solid neoplasm 2Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

cMET-dysregulated Advanced Solid Tumors 1Solid Tumours 1

Interventions

Cisplatin 70Paclitaxel 68pembrolizumab 65Carboplatin 61Irinotecan 59Injections 53Gemcitabine 53Docetaxel 49Fluorouracil 35Cyclophosphamide 35Pemetrexed 34Oxaliplatin 31Capecitabine 30Bevacizumab 29Leucovorin 27atezolizumab 23Nivolumab 23tislelizumab 19Etoposide 18Cetuximab 17durvalumab 16Temozolomide 16Bortezomib 16alvocidib 15Topotecan 15olaparib 14Sorafenib 14Rifampin 14Itraconazole 14Erlotinib Hydrochloride 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Caffeine × Other solid neoplasm × Clear all
NCT02520752 2020-12-10

A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors

Novartis

Phase 1 Completed
37 enrolled
Other solid neoplasm

cMET-dysregulated Advanced Solid Tumors

NCT03333824 2019-03-25

Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

AstraZeneca

Phase 1 Completed
33 enrolled
Other solid neoplasm

Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡